Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

Status unconfirmed

Conditions studied: Coronary Allograft Vasculopathy (CAV)

In brief

Purpose: To show early feasibility of magnetocardiography (MCG) to identify coronary Cardiac positron emission tomography (PET) is the preferred non-invasive tests to assess for CAV and incorporation of quantitative myocardial blood flow (MBF) assessment improves diagnostic accuracy. Based on ISHLT criteria, the following have been proposed for diagnosis of CAV by PET:

Key facts

Study ID

NCT05751915

Run by

Genetesis Inc.

People needed

40

Starts

2023-05-23

Expected to finish

2024-01-30

Last updated by the study team

2023-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years of age at the time of enrollment
• Willing to provide written informed consent
• Completed cardiac PET within the last 2 weeks
• No changes to medication or intervention since the PET was completed

You may not qualify if…

• Patients unable to fit into device
• Patients unable to lie supine for 5 minutes
• Patients with implanted ferromagnetic objects above the costal margin of the rib cage (implanted pacemakers, cardioverter/defibrillators, infusion pumps, and/or neuro stimulators).
• NOTE: Sternotomy wires stents are acceptable
• Implanted pacemakers or cardioverter/defibrillators
• Implanted infusion pumps and/or neuro stimulators
• Severe claustrophobia

Where it is running

• The Cleveland Clinic — Cleveland, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.